Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Go back to Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $34 at Raymond James

February 22, 2024 12:00 PM EST

Raymond James analyst Danielle Brill raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $34.00 (from $27.00) while maintaining a Outperform rating.

The analyst comments "Last month, HRMY preannounced 4Q Wakix sales and provided preliminary FY24 guidance that came in-line w/... More